Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention

NCT ID: NCT01738100

Last Updated: 2016-07-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-09-30
• Study Completion Date: 2016-12-31

Brief Summary

A 2 by 2 factorial, multicenter, prospective, randomized, open-label, blinded endpoint trial. Patients undergoing primary PCI for STEMI will be eligible. Enrolled patients will be randomly assigned to the ticagrelor group or the clopidogrel group in a 1:1 ratio. After emergent coronary angiography, patients who have thrombolysis in myocardial infarction (TIMI) flow grade <2 in coronary angiogram will be randomized again, to either bolus intracoronary injection of morphine sulfate or saline in a 1:1 ratio. Randomization will be stratified by infarct location (anterior vs. non-anterior), and morphine use for pain control before study enroll (for only intracoronary morphine).

Detailed Description

1.1. Ticagrelor versus Clopidogrel

1. In spite of timely and successful reperfusion with primary percutaneous coronary intervention (PCI), the mortality rate still remains high1 and substantial numbers of patients suffer from subsequent left ventricular dysfunction or heart failure after ST-segment elevation myocardial infarction (STEMI).

2. One of limitations of primary PCI is distal embolization and effective antiplatelet therapy is needed in patients with STEMI.

3. Clopidogrel is a representative P2Y12 receptor antagonist and has shown consistent efficacy in patients with acute coronary syndromes. However, clopidogrel is a prodrug and has to be converted to an active metabolite to inhibit P2Y12 receptor. Therefore, onset of effect is relatively slow, antiplatelet effect is moderate, and response to clopidogrel shows wide individual variability.

4. Ticagrelor is a new, direct, reversible P2Y12 receptor antagonist, which has rapid and potent antiplatelet effect. In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding.

5. However, there has been no data whether ticagrelor can reduce infarct size compared with clopidogrel in patients undergoing primary PCI.

1.2. Intracoronary morphine administration

1. Lethal reperfusion injury accounts for up to 50% of the final size of a myocardial infarct.5,6 Therefore, adjunctive therapy that is effective in preventing lethal reperfusion injury is needed to potentiate the benefits of primary PCI.

2. During the past few decades, a large number of animal studies demonstrated that commonly used opioids could provide cardioprotection against ischemia-reperfusion injury. Opioid-induced preconditioning or postconditioning mimics ischemic preconditioning or ischemic postconditioning.

3. Recent small clinical trial demonstrated the cardioprotective effect of remote ischemic preconditioning and morphine during primary PCI. But this study was small and did not demonstrate the separate effect of morphine-induced cardioprotection.

2. Study Objective

1. To investigate the effects of ticagrelor on myocardial infarct size in patients with STEMI undergoing primary PCI compared with clopidogrel

2. To investigate the effects of morphine-induced cardioprotection during primary PCI in patients with STEMI

Conditions

ST-Segment Elevation Myocardial Infarction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ticagrelor + Intracoronary Morphine

180 mg loading pre-PCI followed by 90 mg bid for 5 days. Intracoronary Morphine Sulfate 3 mg + Saline 3 ml mix.

Group Type: EXPERIMENTAL

Ticagrelor

Intervention Type: DRUG

Morphine Sulfate

Intervention Type: DRUG

Ticagrelor + Intracoronary Saline

180 mg loading pre-PCI followed by 90 mg bid for 5 days. Saline 3 ml intracoronary injection.

Group Type: EXPERIMENTAL

Ticagrelor

Intervention Type: DRUG

Saline

Intervention Type: DRUG

Clopidogrel + Intracoronary Morphine

600 mg loading pre-PCI followed by 75 mg qd for 5 days. Morphine Sulfate 3 mg + Saline 3 ml mix intracoronary injection.

Group Type: EXPERIMENTAL

Clopidogrel

Intervention Type: DRUG

Morphine Sulfate

Intervention Type: DRUG

Clopidogrel + Intracoronary Saline

600 mg loading pre-PCI followed by 75 mg qd for 5 days. Saline 3 ml intracoronary injection.

Group Type: ACTIVE_COMPARATOR

Clopidogrel

Intervention Type: DRUG

Saline

Intervention Type: DRUG

Interventions

Ticagrelor

Intervention Type: DRUG

Clopidogrel

Intervention Type: DRUG

Morphine Sulfate

Intervention Type: DRUG

Saline

Intervention Type: DRUG

Other Intervention Names

Brilinta; Plavix; Morphine; Normal Saline

Eligibility Criteria

Inclusion Criteria

• Subject must be at least 20 years of age.
• Patients undergoing primary PCI for STEMI

• Diagnosis of STEMI: ST-segment elevation >0.1 millivolt in ≥2 contiguous leads or (presumably) new left bundle branch block
• Presence of symptoms less than 12 hours

• TIMI flow grade 0 or 1 of infarct related arteries

Exclusion Criteria

• Known hypersensitivity or contraindication to study medications or contrast
• Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
• Rescue PCI after thrombolysis or facilitated PCI
• Cardiogenic shock or cardiopulmonary resuscitation before randomization
• Known chronic hepatic disease
• Known renal dysfunction (creatinine level 3.0mg/dL or dependence on dialysis).
• Decompensated chronic obstructive pulmonary disease or active asthma at inclusion
• Mechanical ventilation at inclusion
• Brain injury or intracranial hypertension
• Acute alcohol intoxication
• Known ulcerative colitis
• Active epilepsy
• Contraindications to undergo MRI imaging include any of the following

• A cardiac pacemaker or implantable defibrillator; any implanted or magnetically activated device; or any history indicating contraindication to MRI including claustrophobia or allergy to gadolinium
• Current use of oral anticoagulant
• An increased risk of bradycardia

• Sinus node dysfunction, atrioventricular dysfunction, or heart rate <40/min
• Patients receiving clopidogrel 300 mg or more before randomization
• One of followings

• history of intracranial bleeding
• intracranial tumor, arteriovenous malformation or aneurysm
• stroke within past 3 months
• Active bleeding of internal organ or bleeding diathesis
• Acute aortic dissection

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hyeon-Cheol Gwon

OTHER

Sponsor Role: lead

Responsible Party

Hyeon-Cheol Gwon

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Hyeon-Cheol Gwon, MD/PhD

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Center

Locations

Samsung Medical Center

Seoul, Gang nam-Gu, Ilwon-Dong, South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Hyeon-Cheol Gwon, MD/PhD

Role: CONTACT

hcgwon62@gmail.com

82-2-3410-6653

Joo-Yong Hahn, MD/PhD

Role: CONTACT

jyhahn@skku.edu

82-2-3410-6653

Facility Contacts

Hyeon-Cheol Gwon, PhD

Role: primary

hcgwon@skku.edu

82-2-3410-6653

Joo-Yong Hahn, PhD

Role: backup

jy.hahn@samsung.com

82-2-3410-6653

References

Kim EK, Park TK, Yang JH, Song YB, Choi JH, Choi SH, Chun WJ, Choe YH, Gwon HC, Hahn JY. Ticagrelor Versus Clopidogrel on Myocardial Infarct Size in Patients Undergoing Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Apr 25;69(16):2098-2099. doi: 10.1016/j.jacc.2017.02.034. No abstract available.

Reference Type: DERIVED

PMID: 28427585 (View on PubMed)

Gwag HB, Kim EK, Park TK, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Lee SH, Chang SA, Park SJ, Lee SC, Park SW, Jang WJ, Lee M, Chun WJ, Oh JH, Park YH, Choe YH, Gwon HC, Hahn JY. Cardioprotective Effects of Intracoronary Morphine in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Prospective, Randomized Trial. J Am Heart Assoc. 2017 Apr 3;6(4):e005426. doi: 10.1161/JAHA.116.005426.

Reference Type: DERIVED

PMID: 28373244 (View on PubMed)

Other Identifiers

2012-08-010

Identifier Type: -

Identifier Source: org_study_id